Position in ARWR
as of Jun 30, 2026
· filed Jul 7, 2026
Position Value
$316,177
+$106,321 QoQ
Shares Held
3,879
+15.9% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#343
of 497 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ARWR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GAMMA Investing LLC holds $18,803,269 across 254 Biotechnology names. ARWR ranks #15 (1.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,918 | $3,436,378 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,067 | $1,288,857 | |
| 3 | MRNA |
Moderna, Inc.
|
14,479 | $1,013,964 | |
| 4 | INCY |
Incyte Corp
|
8,213 | $931,025 | |
| 5 | TECH |
BIO-TECHNE Corp
|
8,769 | $619,529 | |
| 6 | EXEL |
Exelixis, Inc.
|
11,025 | $599,870 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
14,637 | $518,003 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
4,640 | $403,448 |
All Filings in ARWR
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $316,177 | 3,879 | Shares | Defined | 2026-07-07 | |
| 2026-03-31 | $209,856 | 3,347 | Shares | Defined | 2026-04-06 | |
| 2025-12-31 | $242,257 | 3,649 | Shares | Defined | 2026-01-05 | |
| 2025-09-30 | $90,570 | 2,626 | Shares | Defined | 2025-10-02 | |
| 2025-06-30 | $25,232 | 1,597 | Shares | Defined | 2025-07-14 | |
| 2025-03-31 | $27,709 | 2,175 | Shares | Defined | 2025-04-15 | |
| 2024-12-31 | $10,283 | 547 | Shares | Defined | 2025-01-03 | |
| 2024-09-30 | $4,493 | 232 | Shares | Defined | 2024-10-07 | |
| 2024-06-30 | $12,319 | 474 | Shares | Defined | 2024-07-02 | |
| 2024-03-31 | $17,417 | 609 | Shares | Defined | 2024-04-05 | |
| 2023-12-31 | $3,488 | 114 | Shares | Defined | 2024-02-01 | |
| No filing history on record for this holder in this stock. | ||||||